Table I.
HRs for relapse-free survival based on the expression of fucosylation pathway genes of 217 patients with non-small cell lung cancer.
| Gene | Expression quartile | Patients (n) | Death (n) | Crude HR (95% CI) | Adjusted HRa (95% CI) |
|---|---|---|---|---|---|
| FUT2 | Q1 (0-25%) | 54 | 11 | 1 (Reference) | 1 (Reference) |
| Q2 (25-50%) | 55 | 15 | 1.299 (0.601-2.809) | 1.458 (0.673-3.161) | |
| Q3 (50-75%) | 54 | 12 | 1.023 (0.459-2.277) | 1.255 (0.559-2.817) | |
| Q4 (75-100%) | 54 | 22 | 2.275 (1.125-4.601) | 2.527 (1.228-5.203) | |
| FUT3 | Q1 (0-25%) | 54 | 13 | 1 (Reference) | 1 (Reference) |
| Q2 (25-50%) | 55 | 17 | 1.364 (0.663-2.809) | 2.207 (1.042-4.679) | |
| Q3 (50-75%) | 54 | 10 | 0.736 (0.323-1.679) | 1.027 (0.440-2.395) | |
| Q4 (75-100%) | 54 | 20 | 1.737 (0.864-3.493) | 2.190 (1.073-4.470) | |
| FUT4 | Q1 (0-25%) | 54 | 13 | 1 (Reference) | 1 (Reference) |
| Q2 (25-50%) | 55 | 14 | 1.144 (0.537-2.434) | 0.868 (0.400-1.880) | |
| Q3 (50-75%) | 54 | 11 | 0.843 (0.378-1.883) | 0.869 (0.386-1.954) | |
| Q4 (75-100%) | 54 | 22 | 2.020 (1.016-4.018) | 1.605 (0.791-3.258) | |
| FUT6 | Q1 (0-25%) | 54 | 14 | 1 (Reference) | 1 (Reference) |
| Q2 (25-50%) | 55 | 11 | 0.614 (0.276-1.367) | 0.754 (0.336-1.690) | |
| Q3 (50-75%) | 54 | 12 | 0.803 (0.376-1.715) | 0.834 (0.385-1.805) | |
| Q4 (75-100%) | 54 | 23 | 1.765 (0.920-3.385) | 1.962 (1.018-3.780) | |
| FUT8 | Q1 (0-25%) | 54 | 8 | 1 (Reference) | 1 (Reference) |
| Q2 (25-50%) | 55 | 13 | 1.869 (0.774-4.510) | 1.666 (0.685-4.052) | |
| Q3 (50-75%) | 54 | 18 | 2.511 (1.092-5.777) | 2.489 (1.078-5.748) | |
| Q4 (75-100%) | 54 | 21 | 3.096 (1.371-6.990) | 2.530 (1.112-5.760) | |
| FUT9 | Q1 (0-25%) | 54 | 13 | 1 (Reference) | 1 (Reference) |
| Q2 (25-50%) | 55 | 9 | 0.702 (0.300-1.641) | 0.637 (0.271-1.497) | |
| Q3 (50-75%) | 54 | 17 | 1.535 (0.745-3.162) | 1.496 (0.721-3.106) | |
| Q4 (75-100%) | 54 | 21 | 1.854 (0.928-3.706) | 1.424 (0.698-2.906) | |
| FUT10 | Q1 (0-25%) | 54 | 16 | 1 (Reference) | 1 (Reference) |
| Q2 (25-50%) | 55 | 15 | 0.958 (0.473-1.938) | 0.988 (0.479-2.040) | |
| Q3 (50-75%) | 54 | 13 | 0.840 (0.404-1.745) | 0.947 (0.448-2.000) | |
| Q4 (75-100%) | 54 | 16 | 1.031 (0.516-2.063) | 1.188 (0.578-2.444) | |
| FUT11 | Q1 (0-25%) | 54 | 11 | 1 (Reference) | 1 (Reference) |
| Q2 (25-50%) | 55 | 11 | 1.070 (0.464-2.468) | 1.058 (0.457-2.453) | |
| Q3 (50-75%) | 54 | 16 | 1.629 (0.756-3.511) | 1.394 (0.639-3.039) | |
| Q4 (75-100%) | 54 | 22 | 2.411 (1.168-4.977) | 1.834 (0.868-3.876) | |
| POFUT1 | Q1 (0-25%) | 54 | 11 | 1 (Reference) | 1 (Reference) |
| Q2 (25-50%) | 55 | 13 | 1.266 (0.567-2.827) | 1.030 (0.455-2.331) | |
| Q3 (50-75%) | 54 | 16 | 1.551 (0.720-3.342) | 1.159 (0.527-2.548) | |
| Q4 (75-100%) | 54 | 20 | 2.273 (1.088-4.747) | 1.638 (0.760-3.530) | |
| GMDS | Q1 (0-25%) | 54 | 7 | 1 (Reference) | 1 (Reference) |
| Q2 (25-50%) | 55 | 19 | 3.180 (1.337-7.567) | 2.620 (1.092-6.291) | |
| Q3 (50-75%) | 54 | 18 | 2.916 (1.218-6.983) | 2.656 (1.103-6.396) | |
| Q4 (75-100%) | 54 | 16 | 2.649 (1.089-6.442) | 2.160 (0.881-5.296) | |
| TSTA3 | Q1 (0-25%) | 54 | 9 | 1 (Reference) | 1 (Reference) |
| Q2 (25-50%) | 55 | 16 | 2.069 (0.922-4.645) | 1.847 (0.817-4.175) | |
| Q3 (50-75%) | 54 | 15 | 1.689 (0.731-3.902) | 1.475 (0.632-3.442) | |
| Q4 (75-100%) | 54 | 20 | 2.563 (1.167-5.629) | 2.464 (1.118-5.431) | |
| FUK | Q1 (0-25%) | 54 | 18 | 1 (Reference) | 1 (Reference) |
| Q2 (25-50%) | 55 | 12 | 0.620 (0.299-1.288) | 0.669 (0.318-1.410) | |
| Q3 (50-75%) | 54 | 10 | 0.497 (0.229-1.077) | 0.633 (0.281-1.426) | |
| Q4 (75-100%) | 54 | 20 | 1.062 (0.562-2.008) | 1.052 (0.547-2.024) | |
| FUT1 | Q1 (75-100%) | 54 | 26 | 1 (Reference) | 1 (Reference) |
| Q2 (50-75%) | 55 | 12 | 3.839 (1.406-10.483) | 3.030 (1.094-8.397) | |
| Q3 (25-50%) | 54 | 17 | 2.636 (0.929-7.485) | 1.838 (0.626-5.398) | |
| Q4 (0-25%) | 54 | 5 | 6.768 (2.604-17.591) | 4.469 (1.657-12.051) | |
| FUT5 | Q1 (75-100%) | 54 | 26 | 1 (Reference) | 1 (Reference) |
| Q2 (50-75%) | 55 | 11 | 1.104 (0.487-2.502) | 1.064 (0.467-2.425) | |
| Q3 (25-50%) | 54 | 12 | 1.036 (0.449-2.390) | 1.099 (0.469-2.577) | |
| Q4 (0-25%) | 54 | 11 | 2.882 (1.423-5.836) | 2.619 (1.286-5.332) | |
| FUT7 | Q1 (75-100%) | 54 | 16 | 1 (Reference) | 1 (Reference) |
| Q2 (50-75%) | 55 | 9 | 1.616 (0.822-3.177) | 1.593 (0.809-3.137) | |
| Q3 (25-50%) | 54 | 21 | 0.623 (0.270-1.439) | 0.657 (0.281-1.534) | |
| Q4 (0-25%) | 54 | 14 | 1.133 (0.552-2.321) | 1.130 (0.538-2.371) | |
| POFUT2 | Q1 (75-100%) | 54 | 19 | 1 (Reference) | 1 (Reference) |
| Q2 (50-75%) | 55 | 17 | 1.168 (0.523-2.607) | 1.275 (0.569-2.857) | |
| Q3 (25-50%) | 54 | 13 | 1.510 (0.707-3.223) | 1.634 (0.759-3.520) | |
| Q4 (0-25%) | 54 | 11 | 1.874 (0.891-3.939) | 1.570 (0.741-3.327) | |
| FPGT | Q1 (75-100%) | 54 | 17 | 1 (Reference) | 1 (Reference) |
| Q2 (50-75%) | 55 | 19 | 0.615 (0.266-1.422) | 0.646 (0.278-1.503) | |
| Q3 (25-50%) | 54 | 10 | 1.424 (0.714-2.842) | 1.291 (0.645-2.587) | |
| Q4 (0-25%) | 54 | 14 | 1.309 (0.651-2.633) | 0.958 (0.466-1.971) | |
| SLC35C1 | Q1 (75-100%) | 54 | 14 | 1 (Reference) | 1 (Reference) |
| Q2 (50-75%) | 55 | 17 | 1.825 (0.862-3.866) | 1.759 (0.829-3.733) | |
| Q3 (25-50%) | 54 | 18 | 1.613 (0.755-3.443) | 1.802 (0.835-3.892) | |
| Q4 (0-25%) | 54 | 11 | 1.294 (0.587-2.852) | 1.528 (0.688-3.391) |
a
HR adjusted for age, sex, smoking status, and pathological stage. HR, hazard ratio; CI, confidence interval.